Versant Venture Capital VI, L.P. 13D and 13G filings for Black Diamond Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-08-08 4:48 pm Unchanged |
2024-08-06 | 13D | Black Diamond Therapeutics, Inc. BDTX |
Versant Venture Capital VI, L.P. | 4,328,883 7.700% |
0 (Unchanged) |
Filing |
| 2023-11-09 5:24 pm Unchanged |
2023-08-11 | 13D | Black Diamond Therapeutics, Inc. BDTX |
Versant Venture Capital VI, L.P. | 4,328,883 8.400% |
0 (Unchanged) |
Filing |
| 2020-12-03 4:47 pm Sale |
2020-11-23 | 13D | Black Diamond Therapeutics, Inc. BDTX |
Versant Venture Capital VI, L.P. | 4,328,883 12.000% |
-1,031,634 (-19.25%) |
Filing |
| 2020-11-20 5:32 pm Sale |
2020-11-11 | 13D | Black Diamond Therapeutics, Inc. BDTX |
Versant Venture Capital VI, L.P. | 5,360,517 14.900% |
-980,734 (-15.47%) |
Filing |
| 2020-09-25 4:37 pm Sale |
2020-09-17 | 13D | Black Diamond Therapeutics, Inc. BDTX |
Versant Venture Capital VI, L.P. | 6,341,251 17.700% |
-457,424 (-6.73%) |
Filing |
| 2020-08-21 4:19 pm Sale |
2020-08-12 | 13D | Black Diamond Therapeutics, Inc. BDTX |
Versant Venture Capital VI, L.P. | 6,798,675 18.900% |
-669,608 (-8.97%) |
Filing |